Articles and Videos
Ophthalmology Times: Blog: Cannabinol, a rare cannabinoid, shows unique therapeutic potential in glaucoma
Excerpt from Ophthalmology Times blog. A recent study of cannabinol in in vitro and in vivo glaucoma models, demonstrated encouraging results that may address some...
Ophthalmology Advisor: Cannabinoids May Promote Neuroprotection, Normalize Intraocular Pressure
Excerpt from Ophthalmology Advisor. Using in vitro and in vivo models of glaucoma, cannabinoids (CBs) demonstrated neuroprotection, stopped changes in extracellular matrix (ECM), and normalized intraocular pressure (IOP) levels...
Cannabinoids See Explosive Growth Opportunity | The Dales Report
BayMedica's VP of Commercial Operations, Chris Meiering, joins Shadd Dales of The Dales Report to talk about the growth opportunities in the cannabinoid industry. In...
Source: The Dales Report
InMed at Edison Open House Global Healthcare Conference 2022
InMed's CEO, Eric A. Adams, joins the 2022 Edison Open House Global Healthcare Conference on January 25th. In this discussion, Eric talks about the untapped...
InMed Pharmaceuticals (NASDAQ: INM) “Addressing The Increasing Demand For Rare Cannabinoids”
InMed's CEO, Eric A. Adams, and BayMedica's SVP and GM, Shane Johnson, and VP of Commercial Operations, Chris Meiering, join Tribe Public's Webinar "Addressing the...
Source: Tribe Public
Lytham Partners Winter Conference 2021 – InMed Talks About Addressing the Demand for Rare Cannabinoids
Lytham Partners' Robert Blum speaks with InMed Pharmaceuticals CEO, Eric A. Adams, and BayMedica's VP Commercial Operations, Chris Meiering. In this video, Eric and Chris...
Source: Lytham Partners
